References
- 1. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in down regulation of inflammation and protection from tissue damage. Nature. 2001; 414:916-20.
- 2. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008; 7: 759-70.10.1038/nrd2638
- 3. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007; 14:1315-23.10.1038/sj.cdd.4402132
- 4. Xu Z, Muller RA, Park SS, Boysen PG, Cohen MV, Downey JM. Cardioprotection with adenosine A2 receptor activation at reperfusion. J Cardiovasc Pharmacol. 2005; 46:794-802.
- 5. Sitkovsky MV. Use of the A2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol. 2003; 65: 493-501.12566076
- 6. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007; 292: 82-97.
- 7. Grote K, Drexler H, Schieffer B. Renin-angiotensin system and atherosclerosis. Nephrol Dial Transplant. 2004; 19: 770-3.
- 8. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008; 75:346-59.
- 9. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90:251-62.
- 10. Guo RW, Yang LX, Wang H, Liu B, Lei W. Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regulatory Peptides. 2008; 147: 37-44.
- 11. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clinical Science. 2007; 112:417-28.
- 12. Das UN. Is angiotensin-II an endogenous proinflammatory molecule? Med Sci Monit. 2005; 11: RA155-162.
- 13. Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors, new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol. 2007; 27:2532-9.10.1161/ATVBAHA.107.144154
- 14. Rezaei A, Ardestani SK, Forouzandeh M, Tavangar SM, Khorramizadeh MR, Payabvash S, et al. The effects of N-acetylcysteine on the expression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in hepatic fibrosis in bile duct ligated rats. Hepatol Res. 2008; 38:1252-63.
- 15. Ernens I, Rouy D, Velot E, Devaux Y, Wagner DR. Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils, implication of A2a receptor and cAMP/PKA/Ca2+ pathway. Circ Res. 2006; 99: 590-7.
- 16. Zhao P, Li XG, Yang M, Shao Q, Wang D, Liu S, et al. Hypoxia suppresses the production of MMP-9 by human monocyte-derived dendritic cells and requires activation of adenosine receptor A2b via cAMP/PKA signaling pathway. Mol Immunol. 2008; 45:2187-95.10.1016/j.molimm.2007.12.002
- 17. Fotheringham JA, Mayne MB, Grant JA, Geiger JD. Activation of adenosine receptors inhibits tumor necrosis factor-alpha release by decreasing TNF-alpha mRNA stability and p38 activity. Eur J Pharmacol. 2004; 497:87-95.
- 18. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol. 2005; 78:195-201.
- 19. Kanome T, Watanabe T, Nishio K, Takahashi K, Hongo S, Miyazaki A. Angiotensin II upregulates acyl-CoA: cholesterol acyltransferase-1 via the angiotensin II type 1 receptor in human monocyte-macrophages. Hypertense Res. 2008; 31:1801-10.
- 20. Yuan ZY, Nimata M, Okabe T, Shioji K, Hasegawa K, Kita T, et al. Olmesartan, a novel AT(1) antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol. 2005; 289:H1147-52.
- 21. Hasko G, Pacher P, Deitch EA, Vizi ES. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther. 2007; 113:264-75.
- 22. Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN. Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytic THP-1 cells. J Leukoc Biol. 2004; 76:727-34.
- 23. Thiele A, Kronstein R, Wetzel A, Gerth A, Nieber K, Hauschildt S. Regulation of adenosine receptor subtypes during cultivation of human monocytes: role of receptor in preventing lipopolysaccharide-triggered respiratory burst. Infect Immun. 2004; 72:1349-57.
- 24. Velot E, Hass B, Leonard F, Ernens I, Rolland-Turner M, Schwartz C, et al. Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages. Cardiovasc Res. 2008; 80: 246-54.10.1093/cvr/cvn201
- 25. Majumdar S, Aggarwal BB. Adenosine suppresses activation of nuclear factor-κB selectively induced by tumor necrosis factor in different cell types. Oncogene. 2003; 22:1206-18.
- 26. Ribe D, Sawbridge D, Thakur S, Hussey M, Ledent C, Kitchen I, et al. Adenosine A2A receptor signaling regulation of cardiac NADPH oxidase activity. Free Radic Biol Med. 2008; 44:1433-42.
- 27. Palmer TM, Trevethick MA. Suppression of inflammatory and immune responses by the A2A adenosine receptor: an introduction. Br J Pharmacol. 2008; 153:S27-34.
- 28. Martin L, Pingle SC, Hallam DM, Rybak LP, Ramkumar V. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-α release by reducing calciumdependent activation of nuclear factor-kB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther. 2006; 316:71-8.
- 29. Vincenti MP, Brinckerhoff CE. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol. 2007; 213:355-64.
- 30. Fiotti N, Altamura N, Fisicaro M, Carraro N, Uxa L, Grassi G, et al. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26:1330-6.
- 31. Jijon HB, Walker J, Hoentjen F, Diaz H, Ewaschuk J, Jobin C, et al. Adenosine is a negative regulator of NF-κB and MAPK signaling in human intestinal epithelial cells. Cell Immunol. 2005; 237:86-95.
- 32. Zhang L, Ma Y, Zhang J, Cheng J, Du J. A new cellular signaling mechanism for angiotensin II activation of NF-kappaB: an IkappaB-independent, RSK mediated phosphorylation of p65. Arterioscler Thromb Vasc Biol. 2005; 25:1148-53.10.1161/01.ATV.0000164624.00099.e7
- 33. Martin L, Pingle SC, Hallam DM, Rybak LP, Ramkumar V. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-α release by reducing calciumdependent activation of nuclear factor-κB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther. 2006; 316:71-8.
- 34. Beshesh K, Zhao B, Spight D, Biaggioni I, Feokistov I, Denenberg A, et al. The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J Leukoc Biol. 2002; 72: 1027-37.
- 35. Minguest S, Huber M, Rosenkranz L, Schamel WA, Reth M, Brummer T. Adenosine and cAMP are potent inhibitors of the NF-κB pathway downstream of immunoreceptors. Eur J Immunol. 2005; 35:31-41.10.1002/eji.200425524
- 36. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M. Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol. 2004; 173: 21-4.